Literature DB >> 3162327

Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule.

R Wise1, D Griggs, J M Andrews.   

Abstract

The pharmacokinetics and tissue penetration of five quinolones into inflammatory exudate were studied in healthy volunteers. The compounds studied were norfloxacin (400 mg orally), enoxacin (400 mg intravenously and 600 mg orally), ciprofloxacin (100 mg intravenously and 500 mg orally), ofloxacin (600 mg orally), and pefloxacin (400 mg intravenous). Orally administered ofloxacin and ciprofloxacin were the most rapidly absorbed (time to maximal serum level, 1.2 hours) and enoxacin the least (1.9 hours). The serum levels attained were highest in the case of ofloxacin (after an allowance was made for the higher dose administered). The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours. All agents penetrated well into a mild inflammatory exudate. The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide). A dosing schedule for the quinolones was proposed on the basis of pharmacokinetic parameters and microbiologic activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3162327

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  8 in total

1.  Use of fluoroquinolone antimicrobial agents by cardiovascular and cardiopulmonary surgeons.

Authors:  H C Neu
Journal:  Tex Heart Inst J       Date:  1990

2.  Sequential antibiotic therapy: Effective cost management and patient care.

Authors:  L A Mandell; M G Bergeron; M J Gribble; P J Jewesson; D E Low; T J Marrie; L E Nicolle
Journal:  Can J Infect Dis       Date:  1995-11

3.  Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers.

Authors:  J H Yuk; C H Nightingale; R Quintiliani; K R Sweeney
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

4.  The Role of Fluoroquinolones in the Treatment of Skin and Soft Tissue Infection.

Authors:  Md Rabiul Alam; Ellie Hershberger; Marcus J. Zervos
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

5.  In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin.

Authors:  N Rastogi; K S Goh
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

6.  Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers.

Authors:  D Israel; J G Gillum; M Turik; K Harvey; J Ford; H Dalton; M Towle; R Echols; A H Heller; R Polk
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

7.  Intracellular activities of roxithromycin used alone and in association with other drugs against Mycobacterium avium complex in human macrophages.

Authors:  N Rastogi; V Labrousse; A Bryskier
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

Review 8.  Tissue penetration and clinical efficacy of enoxacin in urinary tract infections.

Authors:  S J Childs
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.